Skip to content

Placebo cagrilintide

DRUG11 trials

Sponsors

Novo Nordisk A/S

Conditions

Diabetes Mellitus, Type 2ObesityObesity or OverweightOverweightType 2 Diabetes Mellitus

Phase 1

Phase 3

A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight
CompletedNCT05394519
Novo Nordisk A/SOverweight, Obesity, Type 2 Diabetes Mellitus
Start: 2023-02-01End: 2025-02-03Updated: 2026-01-28
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
Active, not recruitingNCT05567796
Novo Nordisk A/SObesity
Start: 2022-11-01End: 2026-10-19Target: 3400Updated: 2026-08-31
A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight
CompletedNCT05996848
Novo Nordisk A/SObesity or Overweight
Start: 2023-08-15End: 2025-02-22Updated: 2026-01-09
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
CompletedNCT06065540
Novo Nordisk A/SType 2 Diabetes Mellitus
Start: 2023-09-27End: 2026-01-06Updated: 2026-07-08
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
Active, not recruitingNCT06780449
Novo Nordisk A/SObesity
Start: 2025-02-10End: 2028-10-31Target: 400Updated: 2026-01-20
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RecruitingNCT07253285
Novo Nordisk A/SOverweight, Obesity
Start: 2026-01-08End: 2033-09-20Target: 460Updated: 2026-08-31
A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
RecruitingNCT07745504
Novo Nordisk A/SOverweight, Obesity
Start: 2026-08-04End: 2027-07-06Target: 285Updated: 2026-09-04

Related Papers